Stephanie Graff, Associate Director of Global Oncology and Policy at Brown University, shared a post on X:
“VIKTORIA-1 w PI3K/AKT/mTOR (PAM) pathway Inhibitor gedatolisib + fulvestrant +/- palbo improves PFS in WT as triplet and doublet with different AEs—stomatitis increased, hyperglycemia decreased
But it is IV. Weekly.
With inavo capi alpeli + many 2L orals—where do we need geda?”
You can also read: ESMO 2025 Day 1 Highlights Not to Miss
